Real-world evidence on the survival benefit of immune checkpoint inhibitors in combination with cytotoxic chemotherapy for patients with extensive-disease small-cell lung cancer: the Tokushukai Real World Data Project (TREAD) 06
ICI combination therapy improved survival in real-world patients with ED-SCLC, aligning with the results of pivotal clinical trials. However, their limited efficacy in older adults underscores the need for tailored treatment strategies.
Authors
- Koshi Kataoka
- Tomoya Fukui (ORCID: https://orcid.org/0000-0003-4814-4401)
- Rai Shimoyama (ORCID: https://orcid.org/0000-0001-8601-0442)
- Masataka Taguri (ORCID: https://orcid.org/0000-0001-8902-0056)
- Yoshinori Imamura (ORCID: https://orcid.org/0000-0002-5202-531X)
- Kiyoaki Uryu (ORCID: https://orcid.org/0009-0008-6068-1385)
- Maki Hayashi (ORCID: https://orcid.org/0000-0002-1704-8049)
- Takuya Kakutani
- Hironobu Minami (ORCID: https://orcid.org/0000-0001-8630-9145)
- T. Okuda (ORCID: https://orcid.org/0009-0005-1432-6938)
Institutions
- Tokyo Medical University (JP)
- Kajima Corporation (Japan) (JP)
- Kyoto University (JP)
- Kobe University Hospital (JP)
- University of Fukui Hospital (JP)
- Yao Tokushukai General Hospital (JP)
- Shonan Kamakura General Hospital (JP)
- Kobe University (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-08-27
- DOI
- https://doi.org/10.1186/s12885-025-14701-z
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00